Class: I Level of Evidence A
In patients with NSTE-ACS and high-risk features (e.g. elevated troponin) who are not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor at the time of PCI.
Class: II Level of Evidence A
In patients with NSTE-ACS and high-risk features (e.g. elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor at the time of PCI.
Class: II Level of Evidence B
In patients treated with an early invasive strategy and DAPT with intermediate/high-risk features (e.g. positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy.
The following profiles are not actual patients. Individual examination is required to determine the best course of treatment.
Please see Important Safety Information and Full Prescribing Information.
Symptoms
Medical History
Medications
Physical Examination and Lab Results
Action:
Symptoms
Medical History
Home Medications
Concomitant use of Aggrastat with fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding.
Physical Examination and Lab Results
Action
For renally impairment patients with creatinine clearance ≤60 mL/min a dose adjustment for Aggrastat is required. Renally impaired patients should receive a single bolus (25 mcg/kg within 5 minutes), and a maintenance infusion of 0.075 mcg/kg/min for up to 18 hours.
Symptoms
Medical History
Aggrastat is contraindicated in patients with active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.
Home Medications
Concomitant use of Aggrastat with fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding.
Physical Examination and Lab Results
Action
Symptoms
Medical History
Home Medications
Concomitant use of Aggrastat with fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding.
Physical Examination and Lab Results
Action
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.
* This website is intended for U.S. healthcare professionals only.